Literature DB >> 18322377

Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice.

Anne Eckert1, Susanne Hauptmann, Isabel Scherping, Virginie Rhein, Franz Müller-Spahn, Jürgen Götz, Walter E Müller.   

Abstract

BACKGROUND: Mitochondrial dysfunction has been identified in neurodegenerative disorders including Alzheimer's disease, where accumulation of beta-amyloid (Abeta) and oxidative stress seem to play central roles in the pathogenesis, by probably directly leading to mitochondrial dysfunction.
OBJECTIVE: In order to study the in vivo effect of Abeta load during aging, we evaluated the mitochondrial function of brain cells from transgenic mice bearing either mutant amyloid precursor protein (tgAPP) or mutant amyloid precursor protein and mutant PS1 (tgAPP/PS1) as well as from nontransgenic wild-type littermates. tgAPP mice exhibit onset of Abeta plaques at an age of 6 months, but the intracellular soluble Abeta load is already increased at 3 months of age. In contrast, onset of Abeta plaques starts at an age of 3 months in tgAPP/PS1 mice. In addition, we investigated the effects of different Abeta preparations on mitochondrial function of brain cells from tau transgenic mice.
RESULTS: Of note, mitochondrial damage such as reduced mitochondrial membrane potential and ATP levels can already be detected in the brains from these mice before the onset of plaques. In agreement with our findings in tgAPP mice, soluble Abeta induced mitochondrial dysfunction in brain cells from tau transgenic mice.
CONCLUSION: Our results indicate that mitochondrial dysfunction is exacerbated by the presence of soluble Abeta species as a very early event during pathogenesis. 2008 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18322377     DOI: 10.1159/000113689

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  71 in total

1.  Protective effect of isorhynchophylline against β-amyloid-induced neurotoxicity in PC12 cells.

Authors:  Yan-Fang Xian; Zhi-Xiu Lin; Qing-Qiu Mao; Siu-Po Ip; Zi-Ren Su; Xiao-Ping Lai
Journal:  Cell Mol Neurobiol       Date:  2011-11-01       Impact factor: 5.046

Review 2.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 3.  Synaptic mitochondrial pathology in Alzheimer's disease.

Authors:  Heng Du; Lan Guo; Shirley ShiDu Yan
Journal:  Antioxid Redox Signal       Date:  2011-12-15       Impact factor: 8.401

Review 4.  Therapeutic Strategies and Nano-Drug Delivery Applications in Management of Aging Alzheimer's Disease.

Authors:  Thuy Trang Nguyen; Tuong Kha Vo; Giau Van Vo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Decreased proteolytic activity of the mitochondrial amyloid-β degrading enzyme, PreP peptidasome, in Alzheimer's disease brain mitochondria.

Authors:  Nyosha Alikhani; Lan Guo; Shiqiang Yan; Heng Du; Catarina Moreira Pinho; John Xi Chen; Elzbieta Glaser; Shirley ShiDu Yan
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

6.  Determination of small molecule ABAD inhibitors crossing blood-brain barrier and pharmacokinetics.

Authors:  Jhansi Rani Vangavaragu; Koteswara Rao Valasani; Du Fang; Todd D Williams; Shirley ShiDu Yan
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

7.  Synergistic Protective Effects of Mitochondrial Division Inhibitor 1 and Mitochondria-Targeted Small Peptide SS31 in Alzheimer's Disease.

Authors:  P Hemachandra Reddy; Maria Manczak; XiangLing Yin; Arubala P Reddy
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

8.  Structure-based design and synthesis of benzothiazole phosphonate analogues with inhibitors of human ABAD-Aβ for treatment of Alzheimer's disease.

Authors:  Koteswara R Valasani; Gang Hu; Michael O Chaney; Shirley S Yan
Journal:  Chem Biol Drug Des       Date:  2012-11-14       Impact factor: 2.817

9.  Epoxyeicosatrienoic acids pretreatment improves amyloid β-induced mitochondrial dysfunction in cultured rat hippocampal astrocytes.

Authors:  Pallabi Sarkar; Ivan Zaja; Martin Bienengraeber; Kevin R Rarick; Maia Terashvili; Scott Canfield; John R Falck; David R Harder
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-11-27       Impact factor: 4.733

Review 10.  Senescence-accelerated OXYS rats: a model of age-related cognitive decline with relevance to abnormalities in Alzheimer disease.

Authors:  Natalia A Stefanova; Oyuna S Kozhevnikova; Anton O Vitovtov; Kseniya Yi Maksimova; Sergey V Logvinov; Ekaterina A Rudnitskaya; Elena E Korbolina; Natalia A Muraleva; Nataliya G Kolosova
Journal:  Cell Cycle       Date:  2014-02-17       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.